Literature DB >> 15749865

Mechanisms that limit the in vitro proliferative potential of human CD8+ T lymphocytes.

Marco Migliaccio1, Kenneth Raj, Olivier Menzel, Nathalie Rufer.   

Abstract

Human T lymphocytes can be numerically expanded in vitro only to a limited extent. The cyclin-dependent kinase inhibitor p16(INK4a) is essential in the control of cellular proliferation, and its expression, in epithelial cells, is associated with irreversible growth arrest. Using long-term cultured CD8+ T lymphocytes, we have investigated the role of the p16/pRb pathway in the regulation of T cell proliferation and senescence. In this study, we describe at least two mechanisms that cause replicative growth arrest in cultured lymphocytes. The first one depends on the expression of p16(INK4a) and is directly responsible for the exit of a significant proportion of CD8+ T cells from the proliferative population. This induced p16 expression pattern is observed during each round of mitogen stimulation and is not related to activation-induced cell death. Importantly, knocking down p16(INK4a) expression allows increased proliferation of T cells. The second one is a phenomenon that resembles human fibroblast senescence, but is independent of p16(INK4a) and of telomere attrition. Interestingly, virtually all pRb proteins in the senescent population are found in the active form. Our data indicate that newly synthesized p16(INK4a) limits the proliferation of T lymphocytes that respond to mitogen, but is not required for the loss of mitogen responsiveness called senescence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15749865     DOI: 10.4049/jimmunol.174.6.3335

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Key research opportunities in immune system aging.

Authors:  Susan L Swain; Janko Nikolich-Zugich
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-02-27       Impact factor: 6.053

2.  Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?

Authors:  Arne N Akbar; Sian M Henson
Journal:  Nat Rev Immunol       Date:  2011-04       Impact factor: 53.106

3.  Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade.

Authors:  H Suen; R Brown; S Yang; C Weatherburn; P J Ho; N Woodland; N Nassif; P Barbaro; C Bryant; D Hart; J Gibson; D Joshua
Journal:  Leukemia       Date:  2016-04-22       Impact factor: 11.528

Review 4.  Forging a signature of in vivo senescence.

Authors:  Norman E Sharpless; Charles J Sherr
Journal:  Nat Rev Cancer       Date:  2015-07       Impact factor: 60.716

5.  Expression of p16(INK4a) prevents cancer and promotes aging in lymphocytes.

Authors:  Yan Liu; Soren M Johnson; Yuri Fedoriw; Arlin B Rogers; Hong Yuan; Janakiraman Krishnamurthy; Norman E Sharpless
Journal:  Blood       Date:  2011-01-18       Impact factor: 22.113

Review 6.  Tumor suppressor mechanisms in immune aging.

Authors:  Yan Liu; Norman E Sharpless
Journal:  Curr Opin Immunol       Date:  2009-06-15       Impact factor: 7.486

7.  Shelterin dysfunction and p16(INK4a)-mediated growth inhibition in HIV-1-specific CD8 T cells.

Authors:  Mathias Lichterfeld; Thai Cung; Katherine Seiss; Eric S Rosenberg; Florencia Pereyra; Xu G Yu
Journal:  J Virol       Date:  2012-03-07       Impact factor: 6.549

8.  p16INK4a Expression and Immunologic Aging in Chronic HIV Infection.

Authors:  Susan Pereira Ribeiro; Jeffrey M Milush; Edecio Cunha-Neto; Esper G Kallas; Jorge Kalil; Luiz Felipe D Passero; Peter W Hunt; Steven G Deeks; Douglas F Nixon; Devi SenGupta
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

Review 9.  Immunological considerations of modern animal models of malignant primary brain tumors.

Authors:  Michael E Sughrue; Isaac Yang; Ari J Kane; Martin J Rutkowski; Shanna Fang; C David James; Andrew T Parsa
Journal:  J Transl Med       Date:  2009-10-08       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.